Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05983432 |
|
Recruitment Status :
Recruiting
First Posted : August 9, 2023
Last Update Posted : May 3, 2024
|
Sponsor:
SystImmune Inc.
Information provided by (Responsible Party):
SystImmune Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non Small Cell Lung Cancer NSCLC Lung Cancer Breast Cancer Esophageal Cancer SCLC Small Cell Lung Cancer NPC Nasopharyngeal Cancer | Drug: BL-B01D1 | Phase 1 |
BL-B01D1-LUNG-101 is a global, multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics , and initial efficacy of BL-B01D1 in participants with metastatic or unresectable NSCLC and Other Solid Tumors.
This study will be conducted in two different dosing schedules (Cohort A and Cohort B) and three parts (dose escalation, dose finding and dose expansion). Cohort A will be dosed on Day 1 and Day 8 of a continuous 21-day treatment cycle. Cohort B will be dosed on Day 1 of a continuous 21-day treatment cycle. Each Cohort has different dose groups.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 260 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors |
| Actual Study Start Date : | August 8, 2023 |
| Estimated Primary Completion Date : | July 31, 2024 |
| Estimated Study Completion Date : | September 30, 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Lung cancer
MedlinePlus related topics:
Lung Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: BL-B01D1 administered Day 1 and Day 8 per cycle
BL-B01D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks
|
Drug: BL-B01D1
The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. |
|
Experimental: BL-B01D1 administered Day 1 per cycle
BL-B01D1 will be administered on Day 1 via by intravenous infusion every 3 weeks
|
Drug: BL-B01D1
The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. |
Primary Outcome Measures :
- Participants with Dose-limiting toxicities [ Time Frame: One year ]
Measuring the number of patients Dose-limiting toxicities (DLTs). A DLT is defined as any of the following events that are not clearly due to the underlying disease or extraneous causes:
Hematological toxicities:
- Grade 4 neutrophil count decreased lasting >7 days
- Grade ≥3 febrile neutropenia
- Grade ≥3 platelet count decreased with clinically significant hemorrhage.
Non-Hematological toxicities:
- Death
- Hy's law cases
- Grade ≥3 non-hematological toxicities,
- Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs), [ Time Frame: One year ]Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)
- Participants with abnormal physical examination findings [ Time Frame: One year ]Measure the number of participants with abnormal physical examination findings.
- Participants with ability to care for themselves, daily activity, and physical activity [ Time Frame: One year ]Measure the change in participants with Eastern Clinical Oncology Group (ECOG) Scale of Performance Status. The scale is 0-4 with 0 being the fully active (best outcome) and 4 being completely disabled (worst outcome)
- Participants with abnormal ECG reading [ Time Frame: One year ]Measure the number of participants with abnormal ECG parameters
- Participants with abnormal lab results [ Time Frame: One year ]Measure the number of participants with abnormal clinical laboratory values
- To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses and schedules for recommended dose expansion (RDEs) of BL-B01D1 in metastatic NSCLC [ Time Frame: One year ]Determine the highest BL-B01D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-B01D1 dose administered in the event and MTD cannot be defined.
Secondary Outcome Measures :
- Cmax of BL-B01D1 [ Time Frame: One year ]Calculate maximum (peak) observed concentration of BL-B01D1
- Cmax of anti-EGFR×HER3 antibody [ Time Frame: One year ]Calculate maximum (peak) observed concentration of anti-EGFR×HER3 antibody
- Cmax of free payload ED-04 [ Time Frame: One year ]Calculate maximum (peak) observed concentration of free payload ED-04
- Tmax of BL-B01D1 [ Time Frame: One year ]Calculate time of maximum observed concentration of BL-B01D1
- Tmax of anti-EGFR×HER3 antibody [ Time Frame: One year ]Calculate time of maximum observed concentration of anti-EGFR×HER3 antibody
- Tmax of free payload ED-04 [ Time Frame: One year ]Calculate time of maximum observed concentration of free payload ED-04
- AUC(0-8) of BL-B01D1 [ Time Frame: One year ]Calculate area under the serum concentration-time curve of BL-B01D1 from time 0 to 8 hours
- AUC(0-8) of anti-EGFR×HER3 antibodies [ Time Frame: One year ]Calculate area under the serum concentration-time curve of anti-EGFR×HER3 antibodies from time 0 to 8 hours
- AUC(0-8) of free payload ED-04 [ Time Frame: One year ]Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours
- AUC(last) of BL-B01D1 [ Time Frame: One year ]Calculate area under the serum concentration-time curve up of BL-B01D1 to the last quantifiable time
- AUC(last) anti-EGFR×HER3 antibodies [ Time Frame: One year ]Calculate area under the serum concentration-time curve up of anti-EGFR×HER3 antibodies to the last quantifiable time
- AUC(last) of free payload ED-04 [ Time Frame: One year ]Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time
- Overall Response Rate (ORR) [ Time Frame: One year ]To assess the clinical efficacy of BL-B01D1 as measured by ORR using RECIST criteria v 1.1
- Disease Control Rate (DCR) [ Time Frame: One year ]To assess the clinical efficacy of BL-B01D1 as measured by DCR using RECIST criteria v 1.1
- Time To Response (TTR) [ Time Frame: One year ]To assess the clinical efficacy of BL-B01D1 as measured by TTR using RECIST criteria v 1.1
- Progression-Free Survival (PFS), [ Time Frame: One year ]To assess the clinical efficacy of BL-B01D1 as measured by PFS using RECIST criteria v 1.1
- Overall Survival (OS). [ Time Frame: One year ]To assess the clinical efficacy of BL-B01D1 as measured by OS using RECIST criteria v 1.1
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Sign informed consent
- Expected survival > or = 3months
- Has histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include the following tumor types: Non-Small Cell Lung Cancer, HER2- breast cancer, esophageal cancer, Small Cell Lung Cancer, and Nasopharyngeal Cancer.
- Agree to provide a tumor sample
- Has at least one measurable lesion based on RECIST 1.1
- Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1
Exclusion Criteria:
- Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration
- Subjects with history of severe heart disease
- Active autoimmune diseases and inflammatory diseases
- Other malignant tumors were diagnosed within 5 years
- Subjects with poorly controlled hypertension
- Subjects have Grade 3 lung disease or a history of interstitial lung disease
- Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring therapeutic intervention within the previous 6 months before screening
- Symptoms of active central nervous system metastasis.
- Subjects who have a history of allergies to recombinant humanized antibodies or human mouse chimeric antibodies or any of the components of BL-B01D1
- Subjects have a history of autologous or allogeneic stem cell transplantation
- Known HIV, active tuberculosis, active Hepatitis B virus infection or active Hepatitis C virus infection
- Subjects with active infections requiring systemic treatment
- Participated in another clinical trial within 4 weeks prior to participating in the study
- Other conditions that the investigator believes that it is not suitable for participating in this clinical trial
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05983432
Contacts
| Contact: Ta Barrineau | (425) 453-6841 | tara.barrineau@systimmune.com |
Locations
| United States, California | |
| SystImmune Recruiting Site | Recruiting |
| Orange, California, United States, 92868 | |
| United States, Colorado | |
| SystImmune Recruiting Site | Not yet recruiting |
| Boulder, Colorado, United States, 80045 | |
| United States, Florida | |
| SystImmune Recruiting Center | Recruiting |
| Port Saint Lucie, Florida, United States, 34952 | |
| United States, New Jersey | |
| SystImmune Recruiting Site | Not yet recruiting |
| Hackensack, New Jersey, United States, 07601 | |
| United States, New York | |
| SystImmune Recruiting Center | Recruiting |
| New York, New York, United States, 10065 | |
| United States, South Carolina | |
| SystImmune Recruiting Center | Recruiting |
| Greenville, South Carolina, United States, 29605 | |
| United States, Tennessee | |
| SystImmune Recruiting Center | Recruiting |
| Nashville, Tennessee, United States, 37203 | |
| United States, Texas | |
| SystImmune Recruiting Center | Recruiting |
| Dallas, Texas, United States, 75230 | |
| SystImmune Recruiting Site | Recruiting |
| Houston, Texas, United States, 77030 | |
| United States, Virginia | |
| SystImmune Recruiting Site | Recruiting |
| Fairfax, Virginia, United States, 22031 | |
Sponsors and Collaborators
SystImmune Inc.
Investigators
| Study Director: | Clinical Leader | SystImmune Inc. |
| Responsible Party: | SystImmune Inc. |
| ClinicalTrials.gov Identifier: | NCT05983432 |
| Other Study ID Numbers: |
BL-B01D1-LUNG-101 |
| First Posted: | August 9, 2023 Key Record Dates |
| Last Update Posted: | May 3, 2024 |
| Last Verified: | May 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma Nasopharyngeal Neoplasms Nasopharyngeal Carcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic |
Bronchial Neoplasms Head and Neck Neoplasms Pharyngeal Neoplasms Otorhinolaryngologic Neoplasms Nasopharyngeal Diseases Pharyngeal Diseases Stomatognathic Diseases Otorhinolaryngologic Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |